Singapore will launch clinical trials for the Covid-19 vaccine developed by the Duke-NUS Medical School and the American pharmaceutical firm Arcturus Therapeutics as early as this week, says Straits Times.
‘Lunar-Cov19’ is one of 25 vaccine candidates worldwide to enter the stage of clinical development and will be checked on 108 fit volunteers of varying ages in Singapore, the newspaper added.
The trial will assess the efficacy of the vaccine and its potential to generate the antibodies needed to help the body battle the infection, said Professor Ooi Eng Eong, Deputy Director of Duke-NUS Medical School’s emerging infectious diseases programme.
